Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 act mut Dovitinib endometrial cancer sensitive detail...
FGFR2 mutant Infigratinib endometrial cancer sensitive detail...
PIK3CA R88Q PTEN mut Dactolisib endometrial cancer sensitive detail...
PIK3CA R88Q PTEN mut Everolimus endometrial cancer sensitive detail...
PIK3CA R108H PTEN mut Dactolisib endometrial cancer sensitive detail...
PIK3CA R38C PTEN mut Dactolisib endometrial cancer sensitive detail...
PIK3CA E365K PTEN mut Dactolisib endometrial cancer sensitive detail...
PTEN mutant Dactolisib endometrial cancer sensitive detail...
PTEN mutant Everolimus endometrial cancer sensitive detail...
PIK3CA mutant CH5132799 endometrial cancer sensitive detail...
PIK3CA H1047Y CH5132799 endometrial cancer sensitive detail...
PIK3CA R38C PTEN loss CH5132799 endometrial cancer sensitive detail...
FGFR2 C383R FGFR2 N550K PD173074 endometrial cancer resistant detail...
FGFR2 N549K Ponatinib endometrial cancer sensitive detail...
FGFR2 N549K Dovitinib endometrial cancer decreased response detail...
FGFR2 N549K Cediranib endometrial cancer sensitive detail...
FGFR2 N549K Nintedanib endometrial cancer resistant detail...
FGFR2 N549K Brivanib endometrial cancer no benefit detail...
FGFR2 S252W Ponatinib endometrial cancer sensitive detail...
FGFR2 S252W Cediranib endometrial cancer sensitive detail...
FGFR2 S252W Brivanib endometrial cancer sensitive detail...
FGFR2 S252W Nintedanib endometrial cancer sensitive detail...
FGFR2 wild-type Ponatinib endometrial cancer resistant detail...
FGFR2 S252W Dovitinib endometrial cancer decreased response detail...
FGFR2 - BICC1 FGFR2 - OFD1 Erdafitinib endometrial cancer predicted - sensitive detail...
FGFR2 N549K Debio 1347 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N549K Debio 1347 endometrial cancer sensitive detail...
FGFR2 S252W Debio 1347 endometrial cancer sensitive detail...
PIK3CA mutant Pictilisib endometrial cancer sensitive detail...
PTEN mutant Temsirolimus endometrial cancer no benefit detail...
PTEN mutant GSK2636771 endometrial cancer resistant detail...
PTEN mutant AZD6482 endometrial cancer resistant detail...
PTEN mutant TGX-221 endometrial cancer resistant detail...
PTEN mutant A66 endometrial cancer resistant detail...
PTEN mutant A66 + AZD6482 endometrial cancer sensitive detail...
PTEN mutant A66 + GSK2636771 endometrial cancer sensitive detail...
PIK3CA mutant GDC-0980 endometrial cancer sensitive detail...
PTEN mutant GDC-0980 endometrial cancer sensitive detail...
ALK wild-type Dalantercept endometrial cancer no benefit detail...
CTNNB1 mutant Temsirolimus endometrial cancer predicted - sensitive detail...
PIK3CA mutant Temsirolimus endometrial cancer no benefit detail...
HRAS mutant Trametinib endometrial cancer sensitive detail...
FGFR2 mutant PRN1371 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K AZD4547 endometrial cancer sensitive detail...
FGFR2 N550K AZD4547 endometrial cancer predicted - sensitive detail...
FGFR2 S252W AZD4547 endometrial cancer decreased response detail...
FGFR2 over exp AZD4547 endometrial cancer resistant detail...
FGFR2 wild-type AZD4547 endometrial cancer resistant detail...
FGFR2 amp AZD4547 endometrial cancer sensitive detail...
FGFR2 S252W E7090 endometrial cancer sensitive detail...
PTEN E235* TSC2 G440S Miransertib endometrial cancer sensitive detail...
TSC1 M271T TSC2 L604P Miransertib endometrial cancer sensitive detail...
PIK3CA R93W PIK3CA D350G PTEN R130G Miransertib endometrial cancer sensitive detail...
FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs Infigratinib + Pictilisib endometrial cancer sensitive detail...
FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs Buparlisib + Infigratinib endometrial cancer sensitive detail...
FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs Alpelisib + Infigratinib endometrial cancer sensitive detail...
FGFR2 S252W Derazantinib endometrial cancer sensitive detail...
FGFR2 N549K Derazantinib endometrial cancer sensitive detail...
PIK3CA mutant Alpelisib endometrial cancer sensitive detail...
CTNNB1 mutant Cabozantinib endometrial cancer predicted - sensitive detail...
PIK3CA mutant MK2206 endometrial cancer no benefit detail...
PIK3CA mutant Perifosine endometrial cancer not predictive detail...
FGFR2 K310R FGFR2 N550K Infigratinib + Navitoclax endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K Infigratinib endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K PD173074 endometrial cancer sensitive detail...
FGFR2 C383R AZD4547 endometrial cancer sensitive detail...
FGFR2 C383R Infigratinib endometrial cancer sensitive detail...
FGFR2 C383R PD173074 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K ABT-737 + AZD4547 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K ABT-737 + Infigratinib endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K ABT-737 + PD173074 endometrial cancer sensitive detail...
FGFR2 C383R ABT-737 + AZD4547 endometrial cancer sensitive detail...
FGFR2 C383R ABT-737 + Infigratinib endometrial cancer sensitive detail...
FGFR2 C383R ABT-737 + PD173074 endometrial cancer sensitive detail...
FGFR2 N550K ABT-737 + AZD4547 endometrial cancer sensitive detail...
FGFR2 N550K ABT-737 + Infigratinib endometrial cancer sensitive detail...
FGFR2 N550K ABT-737 + PD173074 endometrial cancer sensitive detail...
FGFR2 N550K PD173074 endometrial cancer predicted - sensitive detail...
FGFR2 N550K Infigratinib endometrial cancer predicted - sensitive detail...
MLH1 negative Dostarlimab-gxly endometrial cancer sensitive detail...
MSH6 negative Dostarlimab-gxly endometrial cancer sensitive detail...
PTEN inact mut LY3023414 endometrial cancer no benefit detail...
PIK3CA act mut LY3023414 endometrial cancer no benefit detail...
FGFR2 N549K RLY-4008 endometrial cancer predicted - sensitive detail...
FGFR2 K310R FGFR2 N549K Futibatinib endometrial cancer predicted - sensitive detail...
FGFR2 N549K Futibatinib endometrial cancer predicted - sensitive detail...
FGFR2 S252W Futibatinib endometrial cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01379534 Phase II Dovitinib A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Completed USA 6
NCT01697566 Phase III Metformin An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting USA 0
NCT01797523 Phase II Letrozole Everolimus Metformin RAD/Letrozole/Metformin Active, not recruiting USA 0
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting USA | CAN 15
NCT01935934 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting USA | CAN 0
NCT02035787 Phase I Metformin Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients Recruiting USA 0
NCT02042495 Phase II Metformin Endometrial Cancer Biomarker Changes Following Exposure to Metformin Withdrawn CAN 0
NCT02188550 Phase II Everolimus + Letrozole Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status USA 0
NCT02269293 Phase I Carboplatin + Paclitaxel + Selinexor Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers Completed USA 0
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting USA 1
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Active, not recruiting USA 2
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting USA 0
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Completed USA | CAN 2
NCT02630823 Phase I Carboplatin + Paclitaxel + Pembrolizumab MK-3475 Immunotherapy in Endometrial Carcinoma Completed USA 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting USA 0
NCT02657928 Phase II Letrozole + Ribociclib Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Active, not recruiting USA 0
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Terminated USA 0
NCT02684227 Phase II Carboplatin + Enzalutamide + Paclitaxel Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer Recruiting USA 0
NCT02715284 Phase I Dostarlimab-gxly A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting USA | CAN 7
NCT02725489 Phase II Durvalumab + FANG vaccine Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Completed USA 0
NCT02728258 Phase II Copanlisib Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Active, not recruiting USA 0
NCT02728830 Phase I Pembrolizumab A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Active, not recruiting USA 0
NCT02788708 Phase I Lenvatinib + Paclitaxel Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Active, not recruiting USA 0
NCT02899793 Phase II Pembrolizumab Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Active, not recruiting USA 0
NCT02912572 Phase II Avelumab + Talazoparib Avelumab Avelumab + Axitinib Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer Recruiting USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Active, not recruiting USA 0
NCT02996825 Phase I Gemcitabine + Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Recruiting USA 0
NCT03016338 Phase II Niraparib Study of Niraparib in Recurrent Endometrial Cancer Active, not recruiting CAN 0
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting USA 0
NCT03099499 Phase II ONC201 Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer Suspended USA 0
NCT03120624 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Recruiting USA 0
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Active, not recruiting USA 3
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Recruiting USA 0
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Active, not recruiting USA | CAN 5
NCT03300557 Phase II Exemestane Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer Active, not recruiting USA 0
NCT03310567 Phase II Epacadostat + Pembrolizumab A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma Withdrawn USA 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03339843 Phase II Abemaciclib Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) Recruiting 2
NCT03394027 Phase II ONC201 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Completed USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting USA 3
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Recruiting USA 1
NCT03474640 Phase I Toripalimab Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Recruiting USA 0
NCT03485729 Phase II ONC201 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Recruiting USA 0
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Recruiting USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03552471 Phase I Mirvetuximab Soravtansine + Rucaparib Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03555422 Phase III Selinexor Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) Recruiting USA | CAN 8
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03572478 Phase Ib/II Nivolumab + Rucaparib Nivolumab Rucaparib Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Terminated USA 0
NCT03617679 Phase I Rucaparib Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Recruiting USA 0
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting USA 1
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA 1
NCT03643510 Phase II Abemaciclib + Fulvestrant Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer Recruiting USA 0
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT03675893 Phase II Abemaciclib + Letrozole Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer Recruiting USA 0
NCT03745950 Phase II Olaparib UTOLA: UTerin OLAparib (UTOLA) Active, not recruiting 1
NCT03748186 Phase I STRO-002 Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers Recruiting USA 1
NCT03835819 Phase II Mirvetuximab Soravtansine + Pembrolizumab A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Recruiting USA 0
NCT03905148 Phase Ib/II BGB-283 + PD-0325901 Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors Recruiting USA 1
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA 4
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Recruiting USA 0
NCT03968406 Phase I Talazoparib Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Recruiting USA 0
NCT03981796 Phase III Carboplatin + Paclitaxel Carboplatin + Dostarlimab-gxly + Paclitaxel A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) Recruiting USA | CAN 17
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04122625 Phase Ib/II Debio 1143 + Nivolumab Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Active, not recruiting USA 2
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting USA 0
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Recruiting 1
NCT04188548 Phase I Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) Recruiting USA 7
NCT04197219 Phase II Axitinib + Pembrolizumab Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Withdrawn 0
NCT04214067 Phase III Pembrolizumab Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer Recruiting USA 1
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04300556 Phase Ib/II MORAb-202 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types Recruiting USA 0
NCT04319757 Phase I ACE1702 + Cyclophosphamide + Fludarabine ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Recruiting USA 0
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Recruiting USA 0
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting USA 0
NCT04463771 Phase II Pemigatinib + Retifanlimab Epacadostat + Retifanlimab Retifanlimab Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204) Recruiting USA 4
NCT04482309 Phase II Trastuzumab deruxtecan A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) Recruiting USA | CAN 14
NCT04491942 Phase I BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Recruiting USA 0
NCT04498520 Phase I Abexinostat + Fulvestrant + Palbociclib Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Withdrawn 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04570839 Phase Ib/II BMS-986207 + COM701 + Nivolumab Nivolumab COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. Recruiting USA 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Recruiting USA 0
NCT04641871 Phase I Sym021 + Sym023 Sym021 + Sym022 Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 2
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Recruiting USA | CAN 2
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04750941 Phase II Copanlisib Study of Copanlisib and Ketogenic Diet Recruiting USA 0
NCT04774419 Phase II Dostarlimab-gxly Radiation and TSR-042 in People With Endometrial Cancer After They Receive Surgery Recruiting USA 0
NCT04781088 Phase II Lenvatinib + Paclitaxel + Pembrolizumab Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting USA 0
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA 7
NCT05039801 Phase I IPN60090 IPN60090 + Pembrolizumab IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT05082025 Phase II Copanlisib + Fulvestrant Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Not yet recruiting USA 0